{"schema_version":"1.0","type":"article","title":"GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌","url":"https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.md","lang":"zh-Hant","date":"2026-06-30","publish_at":"2026-06-30T00:43:58.356Z","updated_at":"2026-06-30","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","疫苗","BD","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年 6 月，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元。這筆交易不是小修小補，而是新任 CEO Luke Miels 上任後，替 GSK 腫瘤版圖打下的一記重拳。","key_points":[],"facts":[],"sections":["01｜GSK 買的不是一家公司，而是兩個即將上市的肺癌入口","02｜十年前賣掉腫瘤，十年後用更高代價買回入場券","03｜Miels 的打法：大併購、中型補強、BD 授權一起來","04｜這筆交易最大風險：買得到資產，不等於賣得好藥","05｜台灣可以怎麼看？這篇別再只看老面孔","結語｜GSK 已經把籌碼推上桌，接下來要看能不能換成真正收入"],"references":[{"title":"[The Guardian: GSK to buy US cancer treatment firm Nuvalent in $10bn deal]","source":"","date":"","url":"https://www.theguardian.com/business/2026/jun/09/gsk-buy-us-cancer-treatment-firm-nuvalent-luke-miels"},{"title":"[Investor's Business Daily: Nuvalent stock surges on GSK acquisition]","source":"","date":"","url":"https://www.investors.com/news/technology/nuvalent-stock-gsk-acquisition/"},{"title":"[MarketWatch: GSK announces its biggest purchase in eight years]","source":"","date":"","url":"https://www.marketwatch.com/story/gsk-just-announced-its-biggest-purchase-in-eight-years-to-rev-up-cancer-portfolio-it-had-previously-wound-down-a95e6065"},{"title":"[Barron's: Nuvalent stock jumps on GSK cancer deal]","source":"","date":"","url":"https://www.barrons.com/articles/nuvalent-stock-gsk-cancer-deal-89443e68"},{"title":"各公司官網與公開資料","source":"","date":"","url":""}],"images":[{"alt":"Facebook 原圖：GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌（圖 1）","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/facebook-01.png"},{"alt":"Facebook 原圖：GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌（圖 2）","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/facebook-02.png"},{"alt":"Facebook 原圖：GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌（圖 3）","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/facebook-03.png"},{"alt":"Facebook 原圖：GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌（圖 4）","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-30）。GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌。https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-30-gsk-nuvalent-oncology-comeback-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}